Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.
about
Complement in monoclonal antibody therapy of cancerTrastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsRebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancerNeutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells.Complement receptor 1 genetic variants contribute to the susceptibility to gastric cancer in chinese populationThe immunohistochemical analysis of membrane-bound CD55, CD59 and fluid-phase FH and FH-like complement inhibitors in cancers of ovary and corpus uteri origin.Ablation of nectin4 binding compromises CD46 usage by a hybrid vesicular stomatitis virus/measles virus.Where does radioimmunotherapy fit in the management of breast cancer?Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.Cytotoxic activity against human neuroblastoma and melanoma cells mediated by IgM antibodies derived from peripheral blood of healthy donors.Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack.Pertuzumab and trastuzumab: the rationale way to synergy.CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity.Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.Integrated MicroRNA-mRNA Analysis Reveals miR-204 Inhibits Cell Proliferation in Gastric Cancer by Targeting CKS1B, CXCL1 and GPRC5A.Complement in cancer: untangling an intricate relationship.A high-performance, non-radioactive potency assay for measuring cytotoxicity: A full substitute of the chromium-release assay targeting the regulatory-compliance objective.Beyond the Role of CD55 as a Complement Component.Hypoxia restrains the expression of complement component 9 in tumor-associated macrophages promoting non-small cell lung cancer progression.Effect of membrane-bound complement regulatory proteins on tumor cell sensitivity to complement-dependent cytolysis triggered by heterologous expression of the α-gal xenoantigen.Complement as a Biological Tool to Control Tumor Growth
P2860
Q26860800-4A069210-626F-4DF7-8A65-0A3F12890100Q33644305-CDDE6E95-1F00-4827-B235-AF1589FBBA02Q34922631-716F4B36-1340-4FB7-80E2-2E8809D38974Q35506520-02E5A055-632E-475D-8194-44BF5B7D2861Q35631618-59EA5902-9DAD-4D60-97C0-EEE6B6DA500EQ36305634-1ADB16AA-38CB-4736-820E-1D13AFC29075Q37547082-DF8CD86E-6DB5-461E-B20C-602013F1A060Q38125535-580A3741-383F-40D5-A746-C36FE675D128Q38291696-DD53270C-8837-4AF7-B65D-5E64CB5C8A68Q38797726-A6E6DDA2-29F8-49BE-8BD8-E9AF6458C4E6Q38940506-A7349BFA-783D-48BB-8B25-B4C67B24294CQ39701009-6C2DBCFF-A105-4552-80E5-4EDFCFA355BDQ41612157-2924532E-3CCE-4A99-B64D-64F8B8CA45EEQ48102534-A2B70B89-22E0-49D2-A07E-C0CE1C187D09Q48165470-2F73012C-1DB8-4D77-B0B1-0DCE551E8941Q49236880-20C8B19F-14AC-41AE-B40E-13B2AEB9005AQ50049007-3C53031A-2C9B-4304-83EF-29421B4C03ABQ50192844-56FB2AEE-93CA-43DC-A838-51AD631507D2Q50338802-E9AA6EA8-AE70-40C7-B069-510EC470593EQ55024293-0795DE66-765D-474D-9773-52948FA65A7AQ55154176-58DBC431-584C-4680-8D16-33F7445A32C3Q57492005-F79B4577-6FBB-41EE-AD94-F566BAA11F44
P2860
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Lipoplex mediated silencing of ...... of trastuzumab and pertuzumab.
@en
Lipoplex mediated silencing of ...... of trastuzumab and pertuzumab.
@nl
type
label
Lipoplex mediated silencing of ...... of trastuzumab and pertuzumab.
@en
Lipoplex mediated silencing of ...... of trastuzumab and pertuzumab.
@nl
prefLabel
Lipoplex mediated silencing of ...... of trastuzumab and pertuzumab.
@en
Lipoplex mediated silencing of ...... of trastuzumab and pertuzumab.
@nl
P2093
P2860
P1433
P1476
Lipoplex mediated silencing of ...... of trastuzumab and pertuzumab.
@en
P2093
Marc Cinci
Max Hasmann
Michael Kirschfink
Srinivas Mamidi
Volker Fehring
P2860
P304
P356
10.1016/J.MOLONC.2013.02.011
P577
2013-02-20T00:00:00Z